FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity
Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its Supplemental Biologics ...
Ipsen (GB:0MH6) announced an update on their ongoing clinical study. Study Overview: Ipsen recently completed a study titled A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, ...
Allergan plc, a global pharmaceutical leader, announced that the US Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for Botox for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results